Suppr超能文献

探索结果迷宫:对遗传神经发育障碍和智力残疾临床试验中的结果与工具的范围综述

Navigating the outcome maze: a scoping review of outcomes and instruments in clinical trials in genetic neurodevelopmental disorders and intellectual disability.

作者信息

Müller Annelieke R, van Silfhout Nadia Y, den Hollander Bibiche, Kampman Dick H C, Bakkum Lianne, Brands Marion M M G, Haverman Lotte, Terwee Caroline B, Schuengel Carlo, Daams Joost, Hessl David, Wijburg Frits A, Boot Erik, van Eeghen Agnies M

机构信息

Department of Pediatrics, Emma Children's Hospital, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.

Advisium, 's Heeren Loo, Amersfoort, Utrecht, The Netherlands.

出版信息

Ther Adv Rare Dis. 2024 Apr 25;5:26330040241245721. doi: 10.1177/26330040241245721. eCollection 2024 Jan-Dec.

Abstract

BACKGROUND

Individuals with genetic neurodevelopmental disorders (GNDs) or intellectual disability (ID) are often affected by complex neuropsychiatric comorbidities. Targeted treatments are increasingly available, but due to the heterogeneity of these patient populations, choosing a key outcome and corresponding outcome measurement instrument remains challenging.

OBJECTIVES

The aim of this scoping review was to describe the research on outcomes and instruments used in clinical trials in GNDs and ID.

ELIGIBILITY CRITERIA

Clinical trials in individuals with GNDs and ID for any intervention over the past 10 years were included in the review.

SOURCES OF EVIDENCE

MEDLINE, PsycINFO, and Cochrane CENTRAL were searched. Titles and abstracts were independently screened for eligibility with a subsample of 10% double-screening for interrater reliability. Data from full texts were independently reviewed. Discrepancies were discussed until consensus was reached.

CHARTING METHODS

Information was recorded on patient populations, interventions, designs, outcomes, measurement instruments, and type of reporter when applicable. Qualitative and descriptive analyses were performed.

RESULTS

We included 312 studies reporting 91 different outcomes, with cognitive function most frequently measured (28%). Various outcome measurement instruments ( = 457) were used, with 288 in only a single clinical trial. There were 18 genetic condition-specific instruments and 16 measures were designed ad-hoc for one particular trial. Types of report included proxy-report (39%), self-report (22%), clinician-report (16%), observer-report (6%), self-assisted report (1%), or unknown (16%).

CONCLUSION

This scoping review of current practice reveals a myriad of outcomes and outcome measurement instruments for clinical trials in GNDs and ID. This complicates generalization, evidence synthesis, and evaluation. It underlines the need for consensus on suitability, validity, and relevancy of instruments, ultimately resulting in a core outcome set. A series of steps is proposed to move from the myriad of measures to a more unified approach.

摘要

背景

患有遗传性神经发育障碍(GNDs)或智力残疾(ID)的个体常受到复杂的神经精神共病影响。针对性治疗越来越多,但由于这些患者群体的异质性,选择关键结局及相应的结局测量工具仍然具有挑战性。

目的

本范围综述的目的是描述关于GNDs和ID临床试验中使用的结局及工具的研究。

纳入标准

本综述纳入过去10年中针对GNDs和ID个体进行的任何干预措施的临床试验。

证据来源

检索了MEDLINE、PsycINFO和Cochrane CENTRAL。对标题和摘要进行独立筛选以确定是否符合纳入标准,并对10%的样本进行双人筛选以评估评分者间信度。对全文数据进行独立审查。讨论分歧直至达成共识。

制表方法

记录适用时关于患者群体、干预措施、设计、结局、测量工具及报告者类型的信息。进行定性和描述性分析。

结果

我们纳入了312项报告91种不同结局的研究,其中认知功能测量最为频繁(28%)。使用了各种结局测量工具(n = 457),其中288种仅在一项临床试验中使用。有18种针对特定遗传疾病的工具,16种是为一项特定试验专门设计的。报告类型包括代理报告(39%)、自我报告(22%)、临床医生报告(16%)、观察者报告(6%)、自我辅助报告(1%)或未知(16%)。

结论

本次对当前实践的范围综述揭示了GNDs和ID临床试验中大量的结局及结局测量工具。这使得概括、证据综合和评估变得复杂。它强调了在工具的适用性、有效性和相关性方面达成共识的必要性,最终形成核心结局集。提出了一系列步骤,以从众多测量方法转向更统一的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fa4/11047260/141bd5c0fdf2/10.1177_26330040241245721-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验